RAY B Stock Overview
RaySearch Laboratories AB (publ), a medical technology company, develops software solutions for cancer treatment in the Asia-Pacific, the Middle East, the Americas, Europe, and Africa.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for RAY B from our risk checks.
RaySearch Laboratories AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | kr116.60 |
| 52 Week High | kr123.80 |
| 52 Week Low | kr55.60 |
| Beta | 1.23 |
| 1 Month Change | 8.77% |
| 3 Month Change | 24.71% |
| 1 Year Change | 57.57% |
| 3 Year Change | 29.70% |
| 5 Year Change | -1.44% |
| Change since IPO | 20,476.71% |
Recent News & Updates
Recent updates
RaySearch Laboratories (STO:RAY B) Will Want To Turn Around Its Return Trends
Oct 04
Does RaySearch Laboratories (STO:RAY B) Have A Healthy Balance Sheet?
Jul 10Is RaySearch Laboratories (STO:RAY B) Using Too Much Debt?
Nov 17One Forecaster Is Now More Bearish On RaySearch Laboratories AB (publ) (STO:RAY B) Than They Used To Be
Mar 15Is RaySearch Laboratories (STO:RAY B) A Risky Investment?
Feb 22Is RaySearch Laboratories (STO:RAY B) Using Debt In A Risky Way?
Nov 04Is RaySearch Laboratories (STO:RAY B) Using Debt In A Risky Way?
Mar 30What Kind Of Shareholders Hold The Majority In RaySearch Laboratories AB (publ)'s (STO:RAY B) Shares?
Feb 23RaySearch Laboratories' (STO:RAY B) Shareholders Are Down 41% On Their Shares
Feb 02RaySearch Laboratories AB (publ)'s (STO:RAY B) Stock is Soaring But Financials Seem Inconsistent: Will The Uptrend Continue?
Jan 13
These 4 Measures Indicate That RaySearch Laboratories (STO:RAY B) Is Using Debt Reasonably Well
Dec 26Shareholder Returns
| RAY B | SE Healthcare Services | SE Market | |
|---|---|---|---|
| 7D | -1.2% | 1.9% | -1.7% |
| 1Y | 57.6% | 21.0% | 8.1% |
Return vs Industry: RAY B exceeded the Swedish Healthcare Services industry which returned 21.7% over the past year.
Return vs Market: RAY B exceeded the Swedish Market which returned 8.8% over the past year.
Price Volatility
| RAY B volatility | |
|---|---|
| RAY B Average Weekly Movement | 5.1% |
| Healthcare Services Industry Average Movement | 5.8% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in SE Market | 13.0% |
| 10% least volatile stocks in SE Market | 3.4% |
Stable Share Price: RAY B's share price has been volatile over the past 3 months.
Volatility Over Time: RAY B's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 388 | Johan Lof | www.raysearchlabs.com |
RaySearch Laboratories AB (publ), a medical technology company, develops software solutions for cancer treatment in the Asia-Pacific, the Middle East, the Americas, Europe, and Africa. It develops and markets RayStation, a treatment planning system; RayPlan, a treatment planning system for supporting a range of treatment planning activities for 3D-CRT, IMRT, VMAT, tomotherapy, and electron beam radiation therapy; and RayCare, an oncology information. In addition, it offers µ-RayStation, a software platform for planning and evaluation in small animal irradiation research; RayCommand, a treatment control system that serves as link between the treatment machine and the treatment planning and oncology information systems; and RayIntelligence, a cloud-based oncology analytics system that turns patient data into insights.
RaySearch Laboratories AB (publ) Fundamentals Summary
| RAY B fundamental statistics | |
|---|---|
| Market cap | kr4.00b |
| Earnings (TTM) | kr81.57m |
| Revenue (TTM) | kr1.02b |
49.0x
P/E Ratio3.9x
P/S RatioIs RAY B overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RAY B income statement (TTM) | |
|---|---|
| Revenue | kr1.02b |
| Cost of Revenue | kr106.58m |
| Gross Profit | kr915.58m |
| Other Expenses | kr834.01m |
| Earnings | kr81.57m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 26, 2024
| Earnings per share (EPS) | 2.38 |
| Gross Margin | 89.57% |
| Net Profit Margin | 7.98% |
| Debt/Equity Ratio | 0.1% |
How did RAY B perform over the long term?
See historical performance and comparisonDividends
0.6%
Current Dividend Yield29%
Payout RatioDoes RAY B pay a reliable dividends?
See RAY B dividend history and benchmarks| RaySearch Laboratories dividend dates | |
|---|---|
| Ex Dividend Date | May 23 2024 |
| Dividend Pay Date | May 29 2024 |
| Days until Ex dividend | 35 days |
| Days until Dividend pay date | 41 days |
Does RAY B pay a reliable dividends?
See RAY B dividend history and benchmarks